MIAMI--(BUSINESS WIRE)--Jan. 19, 2006--IVAX Diagnostics, Inc. (AMEX:IVD) announced today that, following communications with the United States Food and Drug Administration (FDA), it now plans to submit a 510(k) application for its PARSEC(TM) System. As a result, commercial deliveries of the PARSEC(TM) System in the United States will await regulatory clearance of the 510(k), which is anticipated during the second or third quarter of 2006. Commercial activities outside of the United States will not be impacted by this process, and deliveries to customer laboratories abroad have already begun and will continue.
